On June 11, Cygnus Biosciences (Beijing) co., Ltd. (“Cygnus Biosciences”), a project invested by Qihang Funs under the ZGC Development Group, announces that it had completed its Series C round funding, which was initiated by Guangzhou High-tech Zone Sci-tech Holding Group co., Ltd. (“High-tech Holding”) and supported by Jinhe Capital. This is the fourth round of fincnding for Cygnus Biosciences. 

Cygnus Biosciences was founded in 2015. Due to competitive price and high-throughout, its next-generation genome sequencing technology (known as NGS) is popular in domestic and foreign market.  

At present, the gene sequencer independently developed by Cygnus Biosciences has passed the laboratory prototype test. In 2021, the product will enter the phase of external testing (clinical trial), and the company will file the registration application.

In the future, Qihang Funds will continue to follow the investment philosophy of the ZGC Development Group, supporting the transformation and industrialization of scientific research achievements from high-end leading talents, cutting-edge research institutions and corporate champions.